ArticleFrontiers in oncology2025
Nomogram to predict hemorrhage risk related to anti-tumor therapy in patients with acute leukemia.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to identify clinical characteristics associated with hemorrhagic events in acute leukemia patients who received anti-tumor therapies and to develop and evaluate a prediction nomogram for hemorrhagic events based on those characteristics. Method: This retrospective cohort study included 468 acute leukemia patients, excluding those with acute promyelocytic leukemia, treated at The Shanghai Fifth People's Hospital and Nanyang Municipal Central Hospital between January 2013 and December 2023. The primary endpoint was World Health Organization (WHO) grade 2 or higher hemorrhagic events related to anti-tumor therapy. Patients were randomly divided into training and test groups at a ratio of 7:3. In the training group, univariable logistic analysis and least absolute shrinkage and selection operator (LASSO) regression were performed to identify significant predictors, which were then used to construct a prediction nomogram for hemorrhage risk. Nomogram performance was evaluated by receiver operating characteristic (ROC) curve analysis, calibration curve analysis, and decision curve analysis (DCA). The following five independent variables were identified as predictors of anti-tumor therapy-related hemorrhagic events in acute leukemia patients and used to develop a prediction nomogram: infection status, types of different hemorrhage prevention drugs and blood products administered, platelet (PLT) transfusion, hematocrit, and PLT count. Result: On ROC curve analysis, the nomogram exhibited satisfactory performance in both the training group [area under the ROC curve (AUC)=0.741] and test group (AUC=0.718). Calibration plots showed a high degree of consistency between the actual and nomogram-predicted survival rates in both groups, and the nomogram showed good clinical utility on DCA. We successfully developed and validated a nomogram for predicting the risk of anti-tumor therapy-related hemorrhage of WHO grade 2 or higher among patients with acute leukemia. Conclusion: This nomogram may provide a practical and user-friendly tool for clinical practice once further validated in perspective large cohort or trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.